TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21511109

Group type: EXPERIMENTAL
Intervention: Regional myocardial dysfunction (RMD)
Number of subjects: 4510
Study: 21513539

Group type: EXPERIMENTAL
Intervention: Audit and feedback intervention for healthcare providers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guidelines distribution at both sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unit-level feedback at the intervention site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre/post surveys of awareness and familiarity (knowledge)
Number of subjects: 0
Study: 21513761

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV), single intranasal dose.
Number of subjects: 200
Study: 21514658

Group type: EXPERIMENTAL
Intervention: Rechallenged with bites of five mosquitoes infected with P falciparum
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (newly recruited malaria-naive volunteers)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In-vitro assays of immune volunteers
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adverse events in immune volunteers
Number of subjects: 6
Study: 21516509

Group type: EXPERIMENTAL
Intervention: PD-0325901 at 20 mg BID for 21 days followed by 7 days off (initial dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PD-0325901 at 15 mg BID (changed dose)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PD-0325901 (overall treatment)
Number of subjects: 13
Study: 21518043

Group type: EXPERIMENTAL
Intervention: Diagnostic questionnaire and algorithm
Number of subjects: 110

Group type: COMPARATOR
Intervention: Reference diagnostic test method (RTM)
Number of subjects: 110
Study: 21518322

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapy (30 mL of bone marrow cultured for MSC growth, injected into one knee)
Number of subjects: 4
Study: 21518586

Group type: EXPERIMENTAL
Intervention: Firebird sirolimus-eluting stent (SES)
Number of subjects: 1029
Study: 21518864

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiinflammatory agents
Number of subjects: 0
Study: 21518985

Group type: EXPERIMENTAL
Intervention: Lapaquistat 100 mg daily
Number of subjects: 6151

Group type: EXPERIMENTAL
Intervention: Lapaquistat 100 mg daily with statin
Number of subjects: 6151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6151
Study: 21519909

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 0
Study: 21523798

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning (RIC) with busulfan, fludarabine, and antithymocyte globulin
Number of subjects: 128
Study: 21524193

Group type: EXPERIMENTAL
Intervention: Higher serum insulin secretion relative to serum glucose after a glucose challenge
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Higher serum adiponectin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Model OL = 232 - 34.9(ln[ratio insulin/glucose]) - 1.4(adiponectin)
Number of subjects: 29
Study: 21524299

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM) and clinic blood pressure monitoring
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Carotid ultrasound to evaluate intima-media thickness (IMT)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Retinal arteriovenous index measurement
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) and ankle-brachial index
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Software for measuring retinal vessel thickness and estimating arteriovenous index
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Endothelial dysfunction markers and other clinical parameters (lipids, creatinine, microalbuminuria, blood glucose, HbA1c, blood insulin, high sensitivity C-reactive protein)
Number of subjects: 300
Study: 21524303

Group type: EXPERIMENTAL
Intervention: Web-based learning kit plus monthly phone calls
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Web-based learning kit plus coaching
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Web-based learning kit plus face-to-face meetings
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Web-based learning kit plus all three methods (monthly phone calls, coaching, face-to-face meetings)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Monthly phone calls (lowest cost intervention)
Number of subjects: 201
Study: 21524447

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest by experienced technicians (n=55)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest by novice technicians (n=30)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (both experienced and novice)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest with at least 4 intimal or medial dissections
Number of subjects: 95

Group type: COMPARATOR
Intervention: Open vein harvest (n=10)
Number of subjects: 95
Study: 21525172

Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 16
Study: 21525850

Group type: EXPERIMENTAL
Intervention: 1.5% glucose and 0.25% L-carnitine
Number of subjects: 4

Group type: COMPARATOR
Intervention: 2.5% glucose solutions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: L-carnitine added to endothelial cells in culture
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: L-carnitine in peritoneal dialysis solution
Number of subjects: 4
Study: 21527026

Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE therapy)
Number of subjects: 9
Study: 21527065

Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 52
Study: 21527127

Group type: EXPERIMENTAL
Intervention: Brief eclectic psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21527129

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine infusion
Number of subjects: 1
Study: 21527169

Group type: EXPERIMENTAL
Intervention: Young men during energy balance
Number of subjects: 32

Group type: COMPARATOR
Intervention: Older men during energy balance
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Young men after underfeeding
Number of subjects: 32

Group type: COMPARATOR
Intervention: Older men after underfeeding
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ad libitum energy intake after underfeeding
Number of subjects: 32
Study: 21529978

Group type: EXPERIMENTAL
Intervention: Glitazone treatment
Number of subjects: 102
Study: 21530362

Group type: EXPERIMENTAL
Intervention: nelfilcon A with enhanced lubricating agents (ELDD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: daily disposable contact lenses (DD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: no contact lenses
Number of subjects: 10
Study: 21530445

Group type: EXPERIMENTAL
Intervention: Conversion from tacrolimus to cyclosporine
Number of subjects: 39
Study: 21531600

Group type: EXPERIMENTAL
Intervention: tesamorelin
Number of subjects: 13
Study: 21531821

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/d (4 weeks on/2 weeks off)
Number of subjects: 26
Study: 21531880

Group type: EXPERIMENTAL
Intervention: Lung Function Questionnaire (LFQ) with a cut point of 18 or less
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Patients scoring 18 or less on the LFQ
Number of subjects: 1575

Group type: EXPERIMENTAL
Intervention: Patients aged 50 years or older scoring 18 or less on the LFQ
Number of subjects: 1575
Study: 21533229

Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag vaccine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ad5 empty vector
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gag-specific T cells
Number of subjects: 70
Study: 21536060

Group type: EXPERIMENTAL
Intervention: Ghrelin levels
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Ghrelin levels in women
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Ghrelin levels in lean individuals (BMI < 22.6 kg/m(2))
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Ghrelin levels in heavier individuals (BMI > 22.6 kg/m(2))
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Restraint (R) and disinhibition (D)
Number of subjects: 308
Study: 21538322

Group type: EXPERIMENTAL
Intervention: Givinostat (ITF2357) administered orally at a dosage of 1.5 mg/kg/day for up to 12 weeks
Number of subjects: 17
Study: 21540203

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted influenza A/California/7/2009(H1N1) virus-like strain flu vaccine
Number of subjects: 1668
Study: 21540460

Group type: EXPERIMENTAL
Intervention: Prophylactic infusion of in vitro-generated donor T cells reactive against CML-associated antigens
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CD8(+) T cells displaying marked cytotoxic activity
Number of subjects: 14
Study: 21541021

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 1995

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1995
Study: 21541799

Group type: EXPERIMENTAL
Intervention: Compression anastomosis using ColonRing™
Number of subjects: 62
Study: 21543424

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 6621
Study: 21543530

Group type: EXPERIMENTAL
Intervention: Diet with 2400 kcal/d
Number of subjects: 21

Group type: COMPARATOR
Intervention: Diet with 3400 kcal/d
Number of subjects: 21
Study: 21543545

Group type: EXPERIMENTAL
Intervention: Relative reinforcing value of food (RRV(food))
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Relative proportion of responding for food compared with reading (RRV(prop))
Number of subjects: 273
Study: 21544866

Group type: EXPERIMENTAL
Intervention: hPTH(1-34) infusion at 2 pmol/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hPTHrP(1-36) infusion at 4 pmol/kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cessation of PTH and PTHrP infusion
Number of subjects: 0
Study: 21545483

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 54
Study: 21546328

Group type: EXPERIMENTAL
Intervention: Nocturnal SBP dipping (defined as ≥ 10% difference in nocturnal systolic blood pressure relative to daytime values)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Nocturnal non-dipping pattern (defined as <10% nocturnal decrease in SBP)
Number of subjects: 663
Study: 21546499

Group type: EXPERIMENTAL
Intervention: R-ACVBP (rituximab, doxorubicine, cyclophosphamide, vindesine, bleomycine, prednisolone) followed by auto-transplantation
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: R-ACVBP
Number of subjects: 209

Group type: COMPARATOR
Intervention: ACVBP (without rituximab)
Number of subjects: 209
Study: 21548959

Group type: EXPERIMENTAL
Intervention: LA-Cr formula (l-arabinose and chromium) after a 70-gram sucrose challenge
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (70 grams of sucrose in water)
Number of subjects: 20
Study: 21548986

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz (EFV) regimen
Number of subjects: 0
Study: 21549867

Group type: EXPERIMENTAL
Intervention: Abdominal visceral adipose tissue (VAT)
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: Abdominal subcutaneous adipose tissue (SAT)
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: Lean body mass (LBM)
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: Race (African American)
Number of subjects: 1081

Group type: EXPERIMENTAL
Intervention: Sex (Male)
Number of subjects: 1081
Study: 21550951

Group type: EXPERIMENTAL
Intervention: Sitagliptin, 100 mg daily
Number of subjects: 108

Group type: COMPARATOR
Intervention: Thiazolidinediones (rosiglitazone, 8 mg daily or pioglitazone, 45 mg daily)
Number of subjects: 108
Study: 21551228

Group type: EXPERIMENTAL
Intervention: Lenalidomide 50 mg daily for 28 days as induction therapy and 10 mg daily for 21 days of a 28-day cycle as maintenance until disease progression or unacceptable toxicity.
Number of subjects: 37
Study: 21551511

Group type: EXPERIMENTAL
Intervention: TNFα inhibitor therapy
Number of subjects: 60
Study: 21553174

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery through single-port incision
Number of subjects: 0
Study: 21553933

Group type: EXPERIMENTAL
Intervention: IgPro20 (subcutaneous administration, 20% solution, initial doses equivalent to 130% of previous IgPro10 doses, adjusted for AUC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: IgPro10 (intravenous administration, 10% solution)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IgPro20
Number of subjects: 18
Study: 21554915

Group type: EXPERIMENTAL
Intervention: A/turkey/Turkey/1/2005 (H5N1) vaccine (3.75 μg HA) with AS03(A)
Number of subjects: 469

Group type: COMPARATOR
Intervention: A/turkey/Turkey/1/2005 (H5N1) vaccine (3.75 μg HA) without AS03(A)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Booster vaccines (adjuvanted or unadjuvanted)
Number of subjects: 469
Study: 21555600

Group type: EXPERIMENTAL
Intervention: Larger grafts (diameter > 8.0 to 9.0 mm)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Grafts 7.0 mm to smaller than 8.0 mm in diameter
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Grafts 8.0 mm in diameter
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Grafts from female donors
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Grafts from male donors
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Younger donor age
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Female donor
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Larger graft size
Number of subjects: 567
Study: 21555610

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab, injected monthly for 6 months
Number of subjects: 17
Study: 21555712

Group type: EXPERIMENTAL
Intervention: Tetraethylammonium chloride (TEA)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-l-arginine (L-NMMA)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 174
Study: 21555744

Group type: COMPARATOR
Intervention: N9-GP (single IV dose at 25, 50, or 100 U/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Previous FIX product (single IV dose at the same dose level)
Number of subjects: 16
Study: 21556142

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) with a 0,1,7-month schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) with a 0,1- or 0,1,2-month schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02(D) with a 0,1,7-month schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Rabies vaccine using the 0,1,2-month schedule
Number of subjects: 0
Study: 21556950

Group type: EXPERIMENTAL
Intervention: Oral vitamin B12 (1500 μg mecobalamin daily for 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular vitamin B12 (1000 μg cyanocobalamin weekly for 5 weeks, then monthly for a total of 3 months)
Number of subjects: 30
Study: 21557878

Group type: EXPERIMENTAL
Intervention: Single-dose intravenous ketamine (0.2 mg/kg)
Number of subjects: 14
Study: 21558357

Group type: EXPERIMENTAL
Intervention: β blockers with inhaled corticosteroid, long acting β agonist, and long acting antimuscarinic
Number of subjects: 5977

Group type: COMPARATOR
Intervention: Control group (inhaled therapy with short acting β agonists or short acting antimuscarinics)
Number of subjects: 5977

Group type: EXPERIMENTAL
Intervention: β blockers
Number of subjects: 5977
Study: 21558401

Group type: EXPERIMENTAL
Intervention: anti-CTLA4 antibody tremelimumab
Number of subjects: 19
Study: 21558987

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m² IV) and Cyclophosphamide (600 mg/m² IV) followed by Paclitaxel (175 mg/m² IV or 80 mg/m² IV) combined with Sorafenib (400 mg oral twice a week) for 12 months or less
Number of subjects: 45
Study: 21561823

Group type: EXPERIMENTAL
Intervention: Ligation of the deep inferior epigastric artery (DIEA)
Number of subjects: 26
Study: 21562045

Group type: EXPERIMENTAL
Intervention: 1.6 mg/m² once weekly (days 1, 8, 15, and 22; 35-day cycles)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 1.3 mg/m² twice weekly (days 1, 4, 8, and 11; 21-day cycles)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 1.3 mg/m² twice weekly
Number of subjects: 70

Group type: COMPARATOR
Intervention: 1.6 mg/m² once weekly
Number of subjects: 70
Study: 21562341

Group type: EXPERIMENTAL
Intervention: 7-day low-sodium intake (51.3 mmol sodium/d)
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: 7-day high-sodium intake (307.8 mmol sodium/d)
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Additive model for SNP rs4073291
Number of subjects: 1906
Study: 21562405

Group type: EXPERIMENTAL
Intervention: Postoperative complications (grade IV complications)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Uneventful course
Number of subjects: 1200

Group type: COMPARATOR
Intervention: All types of investigated procedures
Number of subjects: 1200
Study: 21564455

Group type: EXPERIMENTAL
Intervention: Low-cost and low-resolution genotyping methods
Number of subjects: 421000
Study: 21565903

Group type: EXPERIMENTAL
Intervention: Empirical antifungal therapy
Number of subjects: 397

Group type: COMPARATOR
Intervention: Preemptive antifungal therapy
Number of subjects: 397
Study: 21566065

Group type: EXPERIMENTAL
Intervention: Pelvic-floor muscle (PFM) strengthening program for 4 months
Number of subjects: 23
Study: 21566092

Group type: EXPERIMENTAL
Intervention: alemtuzumab at 30 mg IV 3 times weekly for up to 12 weeks after test dosing
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: alemtuzumab
Number of subjects: 28
Study: 21566413

Group type: EXPERIMENTAL
Intervention: Valrubicin (800 mg, 6 weekly intravesical treatments)
Number of subjects: 90
Study: 21567283

Group type: EXPERIMENTAL
Intervention: Rest rubidium-82 (Rb-82) and FDG PET imaging
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Segments with significant RMM
Number of subjects: 31
Study: 21569187

Group type: EXPERIMENTAL
Intervention: Atazanavir/RTV 300/100 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Atazanavir/RTV 400/100 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Historical controls (nonpregnant adults)
Number of subjects: 41
Study: 21569313

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily for 8 weeks
Number of subjects: 1888
Study: 21569378

Group type: EXPERIMENTAL
Intervention: Atomoxetine treatment for ADHD
Number of subjects: 338
Study: 21569559

Group type: EXPERIMENTAL
Intervention: 12.5 mg/day prednisone
Number of subjects: 60
Study: 21569596

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 29
Study: 21570076

Group type: EXPERIMENTAL
Intervention: Reactive hyperemia (RH)-PAT ratio determined with peripheral arterial tonometry (PAT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Carotid intima media thickness (cIMT) determined by ultrasound
Number of subjects: 54
Study: 21570199

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (gemcitabine, bevacizumab, and radiation therapy)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 26
Study: 21570386

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (4000-40,000 IU/d) with calcium (1200 mg/d)
Number of subjects: 25
Study: 21570508

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Endeavor zotarolimus-eluting stent (ZES)
Number of subjects: 1574
Study: 21571677

Group type: EXPERIMENTAL
Intervention: Stereoscopic digital photographs
Number of subjects: 96

Group type: COMPARATOR
Intervention: Stereoscopic film photographs
Number of subjects: 96
Study: 21572308

Group type: EXPERIMENTAL
Intervention: Lowest tertile of arm skeletal muscle
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Lowest tertile of leg skeletal muscle
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Highest tertile of visceral adipose tissue (VAT)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Lower arm skeletal muscle
Number of subjects: 922
Study: 21575194

Group type: EXPERIMENTAL
Intervention: Trazodone (50-300 mg/day) for 12 weeks
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Trazodone (50-300 mg/day) + Pregabalin (75-450 mg/day) for an additional 12 weeks
Number of subjects: 66
Study: 21576440

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once daily
Number of subjects: 0
Study: 21576653

Group type: EXPERIMENTAL
Intervention: CRT-D (Cardiac Resynchronization Therapy Defibrillator)
Number of subjects: 3253

Group type: COMPARATOR
Intervention: Single-chamber defibrillator
Number of subjects: 3253

Group type: COMPARATOR
Intervention: Dual-chamber defibrillator
Number of subjects: 3253
Study: 21584903

Group type: EXPERIMENTAL
Intervention: Chromosomal copy number alterations (CNAs)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Loss of chromosomal region 15q11.1-q26.3
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Loss of chromosomal region 12p13.31
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Support vector machine (SVM) model
Number of subjects: 95
Study: 21585644

Group type: EXPERIMENTAL
Intervention: Count-to-ten fetal movement counting from pregnancy week 28 until delivery
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: Count-to-ten fetal movement counting in pregnancies with suboptimal outcomes (small-for-gestational-age baby, preterm birth, non-elective caesarean section)
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: Fixed limits for decreased fetal movements (DFMs)
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: Standard approach to fetal movement counting
Number of subjects: 1786
Study: 21586165

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 1211
Study: 21586342

Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine (40/10mg)
Number of subjects: 720

Group type: COMPARATOR
Intervention: perindopril (8 mg) plus amlodipine (10mg)
Number of subjects: 720
Study: 21586746

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 60
Study: 21586916

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment for 12 weeks
Number of subjects: 9
Study: 21587329

Group type: EXPERIMENTAL
Intervention: In-office immunoassay testing (index test)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Liquid chromatography tandem mass spectrometry (LC/MS/MS) (reference test)
Number of subjects: 1000
Study: 21590439

Group type: EXPERIMENTAL
Intervention: Biosimilar epoetin alfa (HX575)
Number of subjects: 1000
Study: 21590520

Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5-15 mg/day)
Number of subjects: 14
Study: 21592098

Group type: EXPERIMENTAL
Intervention: SumaRT/Nap (sumatriptan 85 mg and naproxen 500 mg)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual migraine medication
Number of subjects: 135